Plant-Animal Research Competition

Four Awards ($1,500 each) + publication expenses

We are announcing a competition for external investigator reports dealing with plant-animal communications, which influence animal/human tissues. Eligible studies can vary in their methodology, but state-of-the-art research submissions are encouraged.

Awards Guidelines and Program:
  1. Four Awards granted ($1,500 each) + reimbursement of publication expenses
  2. All reports prepared according to... read more

Published: 2014-12-21

Statin Therapy Decreased the Recurrence Frequency of Atrial Fibrillation after Electrical Cardioversion: A Meta-Analysis

Peng Yan, Pingshuan Dong, Zhijuan Li, Jianxin Cheng

(Department of Cardiology, First Affiliated Hospital, Henan Science and Technology University, Luoyang, Henan, China (mainland))

Med Sci Monit 2014; 20:2753-2758

DOI: 10.12659/MSM.891049

Background: It is unclear whether statin agents provide clinical benefit in preventing the relapse of atrial fibrillation (AF) after electrical cardioversion (EC). The purpose of this study was to assess the effect of statin agents on the recurrence of AF after EC by conducting a meta-analysis of randomized controlled trials (RCTs).
Material and Methods: We conducted a systematic literature search of Medline, EMBASE, ISI Web of Science, and Cochrane databases. RCTs comparing clinical endpoint of the recurrence of AF associated with statin administration vs. no statin treatment (placebo or conventional medical therapy) in patients with AF after EC were eligible. Combined results are presented as risk ratios (RRs) with 95% confidence intervals (CIs).
Results: A total of 5 trials with 524 patients were available for analysis. The pooling analysis showed that statin agents significantly reduced the recurrence of AF after EC compared with no statin treatment (RR=0.76, 95% CI 0.63–0.92; p=0.004; I2=44%). The beneficial effect was shown both in AF subjects receiving atorvastatin or rosuvastatin treatment (atorvastatin 80 mg: RR=0.82, p=0.05; atorvastatin 10 mg: RR=0.27, p=0.03; rosuvastatin: RR=0.38, p=0.04) and in younger patients (<65 years; RR=0.58, p=0.0005). Furthermore, the benefit of statin agents on preventing AF recurrence after EC was demonstrated within 3-month follow-up (p=0.03), and the clinical benefit seemed likely to remain until no less than 12 months after EC (p=0.05).
Conclusions: Based on the currently available data, administration of statin agents, especially atorvastatin or rosuvastatin, is beneficial... read more

Keywords: Atrial Fibrillation, Electric Countershock, Hydroxymethylglutaryl-CoA Reductase Inhibitors

Published: 2014-12-21

NF-κB Signaling Pathway Confers Neuroblastoma Cells Migration and Invasion Ability via the Regulation of...

Yunlai Zhi, Yuhe Duan, Xianjun Zhou, Xiaofeng Yin, Ge Guan, Hong Zhang, Qian Dong, Kun Yang

Med Sci Monit 2014; 20:2746-2752

DOI: 10.12659/MSM.892597

Published: 2014-12-20

Correlation Between Sleep Quality of Third-Trimester Pregnancy and Postpartum Depression

Meifen Wu, Xiaoyi Li, Bin Feng, Hao Wu, Chunbo Qiu, Weifeng Zhang

Med Sci Monit 2014; 20:2740-2745

DOI: 10.12659/MSM.891222